{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.4"},{"groupId":"OG001","value":"75.2"},{"groupId":"OG002","value":"78.8"},{"groupId":"OG003","value":"72.3"}]}],"title":"Progression free at 6 months (%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.2"},{"groupId":"OG001","value":"42.3"},{"groupId":"OG002","value":"67.3"},{"groupId":"OG003","value":"44.6"}]}],"title":"Progression free at 12 months (%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.9"},{"groupId":"OG001","value":"24.4"},{"groupId":"OG002","value":"46.9"},{"groupId":"OG003","value":"25.8"}]}],"title":"Progression free at 18 months (%)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"277"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"65"}],"units":"Participants"}],"description":"Progression-free survival was defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression and was used to assess the efficacy of single agent osimertinib compared with SoC EGFR-TKI therapy as measured by PFS.","groups":[{"description":"Randomized participants received Osimertinib 80 mg orally once daily (QD)","id":"OG000","title":"Osimertinib 80 mg (Global Cohort)"},{"description":"Randomized participant received Standard of care (SoC) Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Participants received gefitinib 250 mg orally QD or erlotinib 150 mg orally QD.","id":"OG001","title":"SoC EGFR-TKI (Global Cohort)"},{"description":"Randomized participants received Osimertinib 80 mg orally once daily (QD)","id":"OG002","title":"Osimertinib 80 mg (China Cohort)"},{"description":"Randomized participant received Standard of care (SoC) Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFRTKI). Participants received gefitinib 250 mg orally QD or erlotinib 150 mg orally QD.","id":"OG003","title":"SoC EGFR-TKI (China Cohort)"}],"paramType":"NUMBER","populationDescription":"The full analysis set (FAS) and China-only FAS. FAS included all randomized participants prior to the end of global recruitment. The China-only FAS included all China participants randomized in mainland-China as part of the global study and all additional China participants recruited in mainland China after global recruitment was completed.","reportingStatus":"POSTED","timeFrame":"At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomisation until progression","title":"Percentage of Participants in Progression Free Survival at 6, 12, and 18 Months","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}